NIH:OVCAR-3
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
NIH:OVCAR-3 |
Humane Ovar Adenokarzinom Zell-Linie |
300307 |
cryovial |
265,00 |
NIH:OVCAR-3 |
Humane Ovar Adenokarzinom Zell-Linie |
330307 |
vital |
335,00 |
| Designation: | NIH:OVCAR-3 |
| Depositor: | Hamilton |
| Organism: | Homo sapiens (human) |
| Ethnicity: | caucasian |
| Age/Stage: | 60 years |
| Gender: | female |
| Tissue: | ovary |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma |
| Growth Properties: | monolayer |
| Description: | The NIH:OVCAR-3 line was established in 1982 by T.C. Hamilton, et al. from the malignant ascites of a patient with progressive adenocarcinoma of the ovary. The cells form colonies in soft agar and have an abnormal karyotype. They are resistant to clinically relevant concentrations of adriamycin, melphalan and cisplatin. Both cultured cells and xenografts exhibit androgen and estrogen receptors. Xenograft models have been used to show that treatment with 17-beta-estradiol can induce progesterone receptors in this human ovarian carcinoma. NIH:OVCAR-3 is an appropriate model system in which to study drug resistance in ovarian cancer, and the presence of hormone receptors should be useful for the evaluation of hormonal therapy. |
| Culture Medium: | RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 µg/ml insulin and 10% fetal bovine serum. |
| Subculturing: | Remove medium and rinse with EDTA (versene) solution. Add fresh 0.025% trypsin/0.02% EDTA (versene) solution, and let the culture sit at 37°C until the cells detach. Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:4 to 1:6 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Negative for mycoplasma: DAPI, PCR Negative for bacteria and fungi: Thioglycollate, CASO-Bouillon EP |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
| DNA Profile (STR): | Amelogenin: X , X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 11,12 D7S820: 10 THO1: 9,9.3 TPOX: 8 vWA: 17 D3S1358: 17,18 D21S11: 29, 31.2 D18S51: 13 Penta E: 7,13 Penta D: 12,13 D8S1179: 10,15 FGA: 21 CLS ∙ Cell Lines Service, 2011. |
| Receptors Expressed: | androgen; estrogen; progesterone |
| Isoenzymes: | G6PD, B; PGM1, 1; PGM3, 1; ES-D, 1; AK-1, 1; GLO-1, 1; Phenotype Frequency Product: 0,0426 |
References: Hamilton TC et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379-89, 1983. Hamilton TC et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J Clin Endocrinol Metab 59: 561-3, 1984. Rogan AM et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-6, 1984. Hamilton TC et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44: 5286-90, 1984. Green JA et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44: 5427-31, 1984. Hamilton TC et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol 11: 285-98, 1984. Godwin AK et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-4, 1992. Caffrey PB and Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res 52: 4812-6, 1992. Chang K et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-40, 1996. Omelyanenko V et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 75: 600-8, 1998. Gawronska B et al. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol 85: 45-52, 2002. Elgqvist J et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 47: 1342-50, 2006. | |
